Chronic Hepatitis C
385
1
2
276
Key Insights
Highlights
Success Rate
91% trial completion (above average)
Published Results
105 trials with published results (27%)
Research Maturity
276 completed trials (72% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
7.0%
27 terminated out of 385 trials
91.1%
+4.5% vs benchmark
32%
123 trials in Phase 3/4
38%
105 of 276 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 276 completed trials
Clinical Trials (385)
Study Comparing the Tolerability and Viral Reduction of the Combination of IFN a-2b XL + Ribavirin Versus Peg IFN a-2b + Ribavirin in Patients With Chronic Hepatitis C, Genotype 1 or 4
Efficacy and Safety Study of Ursodeoxycholic Acid to Treat Chronic Hepatitis C
Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based Therapy
Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Relapser Genotype 2 Hepatitis C Infected Patients
Safety and PK Study of MP-424 to Treat Chronic Hepatitis C
Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Non-responder Genotype 2 Hepatitis C Infected Patients
Study of the Pharmacokinetic Action of Amantadine and Ribavirin in Chronic Hepatitis C. CINAM
Study of the Efficacy and Safety of Pegnano Plus Barivir (Ribavirin) in Treatment-naïve Patients With Chronic Hepatitis C at KienGiang General Hospital
Histologic Changes and Noninvasive Assessment in Hepatitis C Patients Treated with Peginterferon Alpha-2a and Ribavirin
Evaluating Safety and Efficacy In Hepatitis C Patients After PegIntron Pen Treatment (Study P04896)
The Efficacy of Vosevi in Treating DAA-experienced Patients
Pegylated Interferon and Ribavirin in Hepatitis C Patients on Opioid Pharmacotherapy
Natural History of Hepatitis C in Patients With Normal Liver Tests
Pilot Study of Betaine + Combination Antiviral Therapy for Chronic Hepatitis C Genotype 1 Non-responder/Relapsers
Effects of Genotypes on Interferon Signaling in Chronic Hepatitis C
Pilot Comparison of Standard Antiviral Therapy With and Without 12 Weeks of Betaine in Genotype 1 Naive Patients
Changes in Liver Fibrosis, Lipid Profile and Insulin Resistance in HCV Patients Who Received Antiviral Therapy
Treatment of HCV-Infected Recent Injection Drug Users in U.S. Liver Clinics
Add Vitamin D With Standard of Care for Chronic Hepatitis C Patients
Neutrophil Function During Therapy With Protease Inhibitors in Chronic Hepatitis C